The role of baseline HIV-1 resistance testing in patients with established infection
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Effective long-term treatment of HIV-1 infection is challenging because of several factors, including antiretroviral drug resistance. Antiretroviral resistance testing has short-term benefit for optimizing the choice of a rescue regimen after treatment failure. Resistance testing also is recommended before therapy in pregnancy and acute infection or recent seroconversion. The benefit of routine resistance testing before starting treatment for established infection is less clear. This report summarizes the accumulating evidence of persistence of resistant mutants after initial infection, detectability of resistant virus with standard assays before treatment of established infection, the potential adverse impact of this baseline resistance on effectiveness of therapy, and the increasing prevalence of resistance in treatment-naïve patients. Taken together, these data suggest that pretreatment genotypic resistance testing also may be useful in patients with established infection. Although further study is needed, clinicians are now encouraged to routinely obtain pretreatment resistance testing.
- D’Aquila RT, Johnson VA, Welles SL, et al.: Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Ann Intern Med 1995, 122:401–408.
- Lorenzi P, Opravil M, Hirschel B, et al.: Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. AIDS 1999, 13:F17-F21. CrossRef
- Zolopa AR, Shafer RW, Warford A, et al.: HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med 1999, 131:813–821.
- Rosenberg ES, Altfeld M, Poon SH, et al.: Immune control of HIV-1 after early treatment of acute infection. Nature 2000, 407:523–526. CrossRef
- Little SJ, Daar ES, D’Aquila RT, et al.: Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 1999, 282:1142–1149. CrossRef
- Hirsch MS, Brun-Vezinet F, D’Aquila RT, et al.: Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 2000, 283:2417–2426. CrossRef
- Durant J, Clevenbergh P, Halfon P, et al.: Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999, 353:2195–2199. CrossRef
- Baxter JD, Mayers DL, Wentworth DN, et al.: A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000, 14:F83-F93. CrossRef
- Tural C, Ruiz L, Holtzer C, et al.: Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002, 16:209–218. CrossRef
- Cingolani A, Antinori A, Rizzo MG, et al.: Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 2002, 16:369–379. CrossRef
- Meynard JL, Vray M, Morand-Joubert L, et al.: Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 2002, 16:727–736. CrossRef
- Weinstein MC, Goldie SJ, Losina E, et al.: Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med 2001, 134:440–450. This cost effectiveness analysis used a mathematical HIV simulation model to determine the utility of primary and secondary resistance testing. Secondary resistance testing prolonged life and was very cost effective (less than $20,000/QALY in the base-case analysis), and cost effectiveness of primary resistance testing depended on the regional prevalence of transmitted resistance.
- Badri SM, Adeyemi OM, Max BE, et al.: How does expert advice impact genotypic resistance testing in clinical practice? Clin Infect Dis 2003, 37:708–713. CrossRef
- Department of Health and Human Services: Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. November 11, 2003. http://www.aidsinfo.nih.gov/ guidelines/adult/AA_111003.html. Accessed March 15, 2004. This is an exhaustive (92 pages) reference covering all aspects of clinical management of HIV infection. Resistance testing is a small (fewer than two text pages and one table) portion of the document. It is free and easily accessible online in.html or.pdf format.
- Hirsch MS, Brun-Vezinet F, Clotet B, et al.: Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003, 37:113–128. This is the third update by the IAS-USA panel. It includes concise reviews of mechanisms of resistance, resistance assays, and recent clinical trial data. CrossRef
- Hirsch MS, Conway B, D’Aquila RT, et al.: Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. JAMA 1998, 279:1984–1991. CrossRef
- Little SJ, Holte S, Routy JP, et al.: Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002, 347:385–394. This original report is a retrospective analysis of phenotypic and genotypic antiretroviral resistance testing of pretreatment specimens from 377 patients with primary HIV infection who were identified between May 1995 and June 2000 in 10 North American cities. Responses to treatment were evaluated in 202 patients. CrossRef
- Deeks SG, Wrin T, Liegler T, et al.: Virologic and immunologic consequences of discontinuing combination antiretroviraldrug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001, 344:472–480. CrossRef
- Brenner BG, Routy JP, Petrella M, et al.: Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 2002, 76:1753–1761. CrossRef
- Chan KC, Galli RA, Montaner JS, et al.: Prolonged retention of drug resistance mutations and rapid disease progression in the absence of therapy after primary HIV infection. AIDS 2003, 17:1256–1258. CrossRef
- Gandhi RT, Wurcel A, Rosenberg ES, et al.: Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus. Clin Infect Dis 2003, 37:1693–1698. This case report includes a clinical description of a patient who acquired HIV-1 that contained multiple (12) RT and protease mutations and presented with acute infection. A longitudinal analysis of plasma virus pol sequences, drug susceptibility phenotypes, and replication capacity measurements also is presented. The resistance mutations largely persisted in the absence of therapy until the end of follow-up at 1 year after infection acquisition. CrossRef
- Moore CB, John M, James IR, et al.: Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002, 296:1439–1443. CrossRef
- Brown AJ, Precious HM, Whitcomb JM, et al.: Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites. J Virol 2000, 74:10269–10273. CrossRef
- Sonnerburg A, Johansson B, Ayehunie S, et al.: Transmission of zidovudine-resistant HIV-1. AIDS 1993, 7:1684–1685. CrossRef
- Masquelier B, Lemoigne E, Pellegrin I, et al.: Primary infection with zidovudine-resistant HIV. N Engl J Med 1993, 329:1123–1124. CrossRef
- Erice A, Mayers DL, Strike DG, et al.: Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med 1993, 328:1163–1165. CrossRef
- Grant RM, Hecht FM, Warmerdam M, et al.: Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002, 288:181–188. This original report determined trends over time in resistance among recently infected patients in San Francisco, where there is extensive use of ART. Increasing frequency of NNRTI resistance was found, as well as an association of baseline resistance with slower time to viral load suppression. CrossRef
- UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance: Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ 2001, 322:1087–1088. CrossRef
- Violin M, Forbici F, Cozzi-Lepri A, et al.: Primary HIV-1 resistance in recently and chronically infected individuals of the Italian Cohort Naive for Antiretrovirals. J Biol Regul Homeost Agents 2002, 16:37–43.
- Eiros JM, Labayru C, Hernandez B, et al.: Prevalence of genotypic resistance in untreated HIV patients in Spain. Eur J Clin Microbiol Infect Dis 2002, 21:310–313. CrossRef
- Wensing AM, Boucher CA: Worldwide transmission of drugresistant HIV. AIDS Rev 2003, 5:140–155. This paper reviews the mechanisms, magnitude, and implications of worldwide transmission of drug-resistant HIV-1.
- Hanna GJ, Balaguera HU, Freedberg KA, et al.: Drug-selected resistance mutations and non-B subtypes in antiretroviralnaive adults with established human immunodeficiency virus infection. J Infect Dis 2003, 188:986–991. This original report determined that there was a 16% prevalence of drug resistance mutations among drug-naive patients entering HIV care at an inner city Boston hospital in 1999. Plasma specimens left over from pretreatment viral load testing were studied retrospectively using standard genotyping methodology. "Detuned" ELISA testing confirmed that patients had been infected for more than 6 months. CrossRef
- The role of baseline HIV-1 resistance testing in patients with established infection
Current Infectious Disease Reports
Volume 6, Issue 3 , pp 243-249
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links